EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Clinical and Translational Allergy Year : 2012

EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.

1 Section of Allergy and Clinical Immunology
2 Pneumologie et allergologie
3 Pharmacoepidemiologie et évaluation de l'impact des produits de santé sur les populations
4 Department of Allergology
5 Centre for Population Health Sciences
6 Department of Respiratory Medicine
7 The Royal National Throat, Nose and Ear Hospital
8 URL - Upper Airway Research Laboratory
9 Allergy Clinic
10 Division of Immunopathology, Department of Pathophysiology and Allergy Research
11 Department of Internal Medicine, Immunology, Allergy & Respiratory Diseases
12 Pediatric Allergy and Pneumology Unit
13 Swiss Institute of Allergy and Asthma Research (SIAF)
14 CHU Trousseau [APHP]
15 Department of Allergy
16 Department of Paediatrics, Respiratory and Allergic Disease Division
17 Allergy Division
18 Department of Pathophysiology and Allergy Research
19 Department of Experimental Pneumology
20 Allergy and Respiratory Diseases Clinic, Department of Internal Medicine
21 Allergy Section, Department of Internal Medicine
22 Department of Respiratory Diseases
23 Service Pneumologie-Allergologie [CHU Toulouse]
24 Section of Allergy and Clinical Immunology
25 Allergy Unit
26 Facultad de Medicina-UCM
27 RCPH - Research Centre for Prevention and Health
28 Department of Clinical Immunology
29 Allergy & Asthma Center Westend
30 Center for Rhinology and Allergology
31 Krefting Research Centre, Department of Internal Medicine and Clinical Nutrition
32 Seccion de Alergia
33 Institute of Medical Statistics, Informatics and Epidemiology (IMSIE)
34 Department of Pediatrics
35 Pediatric Allergology and Pneumology
36 Department of Pediatrics, Allergy Unit
37 Allergy and Respiratory Diseases
38 Department of Respiratory Medicine and Allergology
39 Allergy Service
40 Clinical Trials Center
41 Suomen Terveystalo Allergy Clinic
42 Division of Respiratory Medicine, Department of Medicine
43 Department of Pulmonology, Intensive Care Medicine
44 Department for Pediatric Pneumology and Immunology
45 UPC Research Laboratories, Allergy Department
Roy Gerth van Wijk
  • Function : Author
  • PersonId : 933590
Aziz Sheikh
  • Function : Author
  • PersonId : 933591
Anthony Frew
  • Function : Author
  • PersonId : 933592
Claus Bachert
  • Function : Author
  • PersonId : 933594
Hans Malling
  • Function : Author
  • PersonId : 933595
Antonio Nieto
  • Function : Author
  • PersonId : 933598
Jocelyne Just
  • Function : Author
  • PersonId : 933600
Carmen Vidal
  • Function : Author
  • PersonId : 933601
Emilio Alvarez-Cuesta
  • Function : Author
  • PersonId : 933603
Albrecht Bufe
  • Function : Author
  • PersonId : 933605
Ronald Dahl
  • Function : Author
  • PersonId : 933608
Stephen Durham
  • Function : Author
  • PersonId : 933610
Peter Eng
  • Function : Author
  • PersonId : 933611
Montserrat Fernandez-Rivas
  • Function : Author
  • PersonId : 933612
Lars Jacobsen
  • Function : Author
  • PersonId : 933613
Marek Jutel
  • Function : Author
  • PersonId : 933614
Jörg Kleine-Tebbe
  • Function : Author
  • PersonId : 933615
Ludger Klimek
  • Function : Author
  • PersonId : 933616
Carmen Moreno
  • Function : Author
  • PersonId : 933618
Antonella Muraro
  • Function : Author
  • PersonId : 933620
Bodo Niggemann
  • Function : Author
  • PersonId : 933621
Giovanni Pajno
  • Function : Author
  • PersonId : 933622
Giovanni Passalacqua
  • Function : Author
  • PersonId : 933623
Oliver Pfaar
  • Function : Author
  • PersonId : 933624
Gianenrico Senna
  • Function : Author
  • PersonId : 933626
Gabriela Senti
  • Function : Author
  • PersonId : 933627
Erkka Valovirta
  • Function : Author
  • PersonId : 933628


ABSTRACT: Allergy today is a public health concern of pandemic proportions, affecting more than 150 million people in Europe alone. In view of epidemiological trends, the European Academy of Allergy and Clinical Immunology (EAACI) predicts that within the next few decades, more than half of the European population may at some point in their lives experience some type of allergy.Not only do allergic patients suffer from a debilitating disease, with the potential for major impact on their quality of life, career progression, personal development and lifestyle choices, but they also constitute a significant burden on health economics and macroeconomics due to the days of lost productivity and underperformance. Given that allergy triggers, including urbanization, industrialization, pollution and climate change, are not expected to change in the foreseeable future, it is imperative that steps are taken to develop, strengthen and optimize preventive and treatment strategies.Allergen specific immunotherapy is the only currently available medical intervention that has the potential to affect the natural course of the disease. Years of basic science research, clinical trials, and systematic reviews and meta-analyses have convincingly shown that allergen specific immunotherapy can achieve substantial results for patients, improving the allergic individuals' quality of life, reducing the long-term costs and burden of allergies, and changing the course of the disease. Allergen specific immunotherapy not only effectively alleviates allergy symptoms, but it has a long-term effect after conclusion of the treatment and can prevent the progression of allergic diseases.Unfortunately, allergen specific immunotherapy has not yet received adequate attention from European institutions, including research funding bodies, even though this could be a most rewarding field in terms of return on investments, translational value and European integration and, a field in which Europe is recognized as a worldwide leader. Evaluation and surveillance of the full cost of allergic diseases is still lacking and further progress is being stifled by the variety of health systems across Europe. This means that the general population remains unaware of the potential use of allergen specific immunotherapy and its potential benefits.We call upon Europe's policy-makers to coordinate actions and improve individual and public health in allergy by:Promoting awareness of the effectiveness of allergen specific immunotherapyUpdating national healthcare policies to support allergen specific immunotherapyPrioritising funding for allergen specific immunotherapy researchMonitoring the macroeconomic and health economic parameters of allergyReinforcing allergy teaching in medical disciplines and specialtiesThe effective implementation of the above policies has the potential for a major positive impact on European health and well-being in the next decade.
Fichier principal
Vignette du fichier
2045-7022-2-20.pdf (185.81 Ko) Télécharger le fichier
2045-7022-2-20.xml (79.84 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Format : Other

Dates and versions

inserm-00761011 , version 1 (04-12-2012)



Moises Calderon, Pascal Demoly, Roy Gerth van Wijk, Jean Bousquet, Aziz Sheikh, et al.. EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy.. Clinical and Translational Allergy, 2012, 2 (1), pp.20. ⟨10.1186/2045-7022-2-20⟩. ⟨inserm-00761011⟩
405 View
507 Download



Gmail Facebook Twitter LinkedIn More